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Schnitzler’s syndrome is a rare autoinflammatory disorder characterized by
interleukin-1ß-mediated and neutrophil-dominated inflammation. Neutrophil extracellular
traps (NETs) are web-like structures of decondensed chromatin, histones, and
antimicrobial peptides released by neutrophils. NETs were initially described in the
context of pathogen defense but are also involved in autoimmune-mediated skin
diseases. Here, we assessed the role of neutrophil extracellular trap formation (NETosis)
in Schnitzler’s syndrome. Immunofluorescence co-staining of myeloperoxidase and
subnucleosomal complex was performed on lesional skin samples from patients with
Schnitzler’s syndrome, other neutrophilic dermatoses (cryopyrin-associated periodic
syndrome, Sweet syndrome, and pyoderma gangrenosum), urticarial vasculitis and
chronic spontaneous urticaria as well as healthy control skin. Blood neutrophils from
patients with Schnitzler’s syndrome and controls were isolated, and NETosis was
induced by phorbol 12-myristate 13-acetate (PMA). Also, NETosis of control neutrophils
induced by symptomatic Schnitzler’s syndrome sera, cytokines and sub-threshold
PMA doses was studied. Immunofluorescence co-staining revealed widespread and
substantial NET formation in lesional skin of Schnitzler’s syndrome patients but absence
of NETs in chronic spontaneous urticaria and control skin. Neutrophils undergoing
NETosis were observed in the skin of other neutrophilic diseases too. Correspondingly,
blood neutrophils from Schnitzler’s syndrome patients showed significantly elevated
NETosis rates compared to control neutrophils following stimulation with PMA. Increased
NETosis correlated well with high levels of C-reactive protein (CRP). SchS patients with
the lowest NETosis rates had persistent joint and bone pain despite IL-1 blockade.
Stimulation of control neutrophils and sub-threshold PMA with sera of symptomatic
Schnitzler’s syndrome patients disclosed enhanced NETosis as compared to control
sera. Our results suggest that the induction of NET formation by neutrophils contributes
to skin and systemic inflammation and may support the resolution of local inflammation
in Schnitzler’s syndrome.
Keywords: Schnitzler’s syndrome, neutrophil extracellular traps, neutrophils, autoinflammation, autoimmunity,
neutrophilic dermatosis
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INTRODUCTION
Schnitzler’s syndrome (SchS) is a rare acquired autoinflammatory
disease defined by recurrent urticarial rash, monoclonal
gammopathy, and systemic inflammation that presents with
fever episodes, muscle, bone, and joint pain (1). Until now, little
is known about the exact pathophysiology of SchS. As in other
autoinflammatory diseases, interleukin-1ß (IL-1β) functions as a
key mediator of inflammation (2). In the skin of SchS patients,
IL-1ß, and related cytokines are upregulated and produced
by dermal mast cells and neutrophils (3, 4). The urticarial
rash in SchS corresponds to neutrophil-rich dermal infiltrates
classified as neutrophilic dermatosis. This term comprises a
heterogeneous group of non-infectious inflammatory skin
diseases characterized by the predominance of neutrophils
in lesional skin (5). The specific role of neutrophils in SchS,
however, is still ill-defined.
Neutrophils are part of the innate immune system and
are responsible for the first line defense against pathogens by
degranulating and secreting granule-stored antibacterial proteins
as well as phagocytosis. Moreover, neutrophils are known
to release neutrophil extracellular traps (NETs), which are
web-like structures of decondensed chromatin, histones, and
antimicrobial peptides that were initially described in the context
of pathogen defense (6). NETs are also involved in various
immune-mediated disorders as well as autoimmune diseases, and
they contribute to the cutaneous inflammation in systemic lupus
erythematosus (SLE) and psoriasis (7, 8). Recently, NETs were
shown to regulate IL-1ß-mediated systemic inflammation in the
autoinflammatory disease familial Mediterranean fever (FMF)
(9) and were linked to arthritic inflammation in patients with
gout (10).
In this study, we assessed NET formation in the lesional skin
and peripheral blood of patients with SchS.
MATERIALS AND METHODS
Patients and Patient Samples
Lesional skin biopsies (ø 3−4mm) were obtained from
symptomatic patients with SchS (based on the Straßbourg
diagnostic criteria (1)) or chronic spontaneous urticaria
(CSU) who were treated at the Department of Dermatology,
Charité - Universitätsmedizin Berlin. At the time of the skin
biopsy, patients did not receive anti-IL-1-therapy or other
immunomodulatory therapies. In addition, lesional skin samples
from patients with Cryopyrin-associated periodic syndrome
(CAPS), urticarial vasculitis (UV), and other neutrophilic
dermatoses (Sweet syndrome [SwS] and pyoderma gangrenosum
Abbreviations: CAPS, Cryopyrin-associated periodic syndrome; CRP, C-reactive
protein; CSU, Chronic spontaneous urticaria; DAPI, 4′,6-Diamidino-2-
phenylindole dihydrochloride; FMF, Familial Mediterranean fever; IL, Interleukin;
IL-1RA, Interleukin-1-receptor antagonist; MPO, Myeloperoxidase; NETs,
Neutrophil extracellular traps; NLRP, Nucleotide binding domain like receptor
protein; PG, Pyoderma gangrenosum; PGA, Physician global assessment; PMA,
Phorbol 12-myristate 13-acetate; SAA, Serum amyloid A; SchS, Schnitzler’s
syndrome; SLE, Systemic lupus erythematosus; SwS, Sweet syndrome; UV,
Urticarial vasculitis.
[PG]) as well as skin samples from healthy control subjects
who underwent bariatric, plastic or breast reduction surgery,
were obtained from the Department of Surgery, Charité—
Universitätsmedizin Berlin. Also, blood samples from SchS
patients (canakinumab-treated within the last 8 weeks and
untreated patients) and healthy donors were taken. Blood
samples were derived from SchS patients who underwent skin
biopsy and from additional SchS patients. The mean disease
duration in SchS patients was 10.45 years when tests were
performed. Skin and blood specimens from individual patients
were obtained at different time points. The study was approved
by the local ethics committee (EA4/005/15, EA1/007/17), and
patients provided written and oral informed consent.
Immunofluorescence Staining of
Skin Samples
Paraffin sections (5µm) of lesional skin (SchS n = 8, CSU n
= 5, CAPS n = 3, UV n = 5, SwS n = 4, PG n = 4) and
healthy control skin (n = 10) were prepared and processed for
immunofluorescence staining. We stained hematoxylin eosin,
myeloperoxidase (MPO) as well as subnucleosomal complex as
a marker for NET formation and used DAPI (4’,6-Diamidino-2-
phenylindole dihydrochloride 10236276001, Roche Diagnostics
Deutschland GmbH, Mannheim) for counterstaining of nuclei.
MPO (1:400 392105 MAB3174 R&D Systems, Inc., Minneapolis,
USA) was incubated with the secondary antibody (1:600 30min
room temperature, Alexa Fluor R© 488-conjugated AffiniPure
goat-anti-mouse IgG, 115-545-146; Jackson Immuno Research,
West Grove, USA) and mouse normal serum 4% was added
(1 h room temperature). The Alexa 488-labeled MPO antibody
(overnight 4◦C) was followed by incubation with Alexa 594
(1:200 30min room temperature, Alexa Fluor R© 594-conjugated
Fab AffiniPure goat-anti-mouse IgG, 115-585-062; Jackson
Immuno Research, West Grove, USA) labeled monoclonal
mouse-anti-human-subnucleosomal complex (Histone 2A, 2B,
chromatin) antibody (1:1,500 1 h room temperature). Samples
of tonsil tissue served as positive controls for staining
MPO and were derived from routine tissue sampling of
the Department of Pathology, Charité – Universitätsmedizin
Berlin. Sections omitting the primary antibody served as
negative controls.
Isolation and Stimulation of Neutrophils
Peripheral blood neutrophils from SchS patients (n = 12;
canakinumab-treated patients n = 9, untreated patients n =
3; Table S1) and healthy controls (n = 12) were isolated by
using a neutrophil isolation kit (MACSxpress R© neutrophil
isolation kit human, MACS Miltenyi Biotec GmbH, Bergisch-
Gladbach, Germany, no. 130-104-434). Neutrophils were
assessed for spontaneous NET formation (incubation with
RPMI medium with 2% fetal calf serum for 130min) and
for NET formation after stimulation with 20 nM phorbol
12-myristate 13-acetate (PMA) for 80, 100, and 130min as
previously described (11). Neutrophils were isolated and
processed in pairs of one patient and one healthy control at
a time.
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In addition, NET formation of healthy control neutrophils
by SchS sera (10% serum concentration) from symptomatic
patients (n = 12), combined with RPMI medium with
2% fetal calf serum as well as sub-threshold (0.05 nM)
PMA doses for 130min, was assessed. Sera from healthy
individuals (n = 14) served as controls. Also, NET
formation of control neutrophils and neutrophils from
SchS patients was assessed after stimulation with IL-1β
(10–50 ng/ml), IL-6 (10–100 ng/ml), IL-17 (20–100 ng/ml),
or IL-8 (20–100 ng/ml) as well as with a combination of
proinflammatory cytokines (IL-1β, IL-6, IL-17, IL-8) and
subthreshold PMA.
FIGURE 1 | Marked NET formation in lesional skin of Schnitzler‘s syndrome (SchS) patient vs. absence of NET formation in chronic spontaneous urticaria (CSU)
patient. Exemplified fluorescence images showing marked and aggregated NET formation characterized by nuclear expansion and extracellular web-like DNA-fibers
(white arrows) in the lesional dermis of a SchS patient vs. absence of NETosis of neutrophils (green arrows) in lesional dermis of a CSU patient. Neutrophils (Alexa
488-MPO–green) undergoing NETosis (subnucleosomal complex Histone H2A, H2B, chromatin Alexa 594–red). Nuclei are counterstained with DAPI (blue) (original
magnification 200x). Overwiew: Hematoxylin-Eosin staining of infiltrate in lesional skin of SchS patient (original magnification 200x).
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NET Detection by Immunofluorescence
Staining and Quantification of NET
Formation of Peripheral Blood and
Skin Neutrophils
Samples were stained (immunofluorescence co-staining of DAPI
and subnucleosomal complex), and microscopic images of
peripheral blood neutrophils were analyzed by ImageJ as
previously described (12). In brief, 5 microscopic images of
each coverslip were randomly taken per experiment (100x
magnification). Image files were loaded in the ImageJ software
and for total cell number, the DAPI fluorescence image stack was
analyzed (automatic particle analysis, 20 pixels minimum size).
For neutrophils undergoing NETosis, the anti-subnucleosomal
complex fluorescence image stack was counted automatically.
To clearly distinguish between non-NETting and NETting
cells, exposure times were calibrated to show no fluorescence
signal in non-stimulated neutrophils (negative control) and
full fluorescence signal of anti-subnucleosomal antibody in
the PMA 130min.-stimulated samples (positive control). We
kept this threshold value of exposure time constant for each
experiment. Relative NETosis rates were calculated by using
the highest NETosis rate per experiment as 100%. NETosis in
the skin was assessed by percentages of neutrophils undergoing
NETosis per high power field. Stainings were analyzed by one
blinded researcher who counted all neutrophils undergoing
NETosis in five exemplified high power fields per skin sample
(400x magnification). Cases of dense neutrophilic infiltration
with wide-spread NETosis covering the HPF, were assessed
as 100%. Exemplified stainings of NETosis were analyzed by
confocal microscopy.
Assessment of Serum Inflammation
Markers and Physician Global Assessment
Sera of canakinumab-treated SchS patients (n = 8) were
analyzed for C-reactive protein (CRP, Ref. <5.0 mg/l), serum
amyloid A (SAA, Ref. <6.4 mg/l), and total blood neutrophil
count (Ref. 1.5–7.7/nl) at the time of neutrophil stimulation.
For analysis of S100A8/9 (Ref. <2.94µg/ml) and interleukin-
1-receptor antagonist (IL-1RA, Ref. <500 pg/ml), sera of n
= 5 canakinumab treated patients were available. We also
assessed quantitative immunoglobulins (IgM, Ref. < 2.3 g/l; IgG,
Ref. 7–16 g/l). In addition, physician global assessment (PGA,
categories: urticarial rash, fatigue, fever, myalgia/bone pain and
arthralgia, score 0–4; maximum score: 20) was performed.
Statistical Analysis
Statistical analysis was performed for non-parametric data
by using the Mann Whitney U-Test. Correlation analyses
for inflammation marker concentrations as well as PGA and
NETosis rates were performed by Spearman’s rank coefficient.
For all analyses, SPSS version 22.0 and Graph Pad Prism version
6.0 were used. Statistical significance was considered by p≤ 0.05.
FIGURE 2 | Confocal microscopic images of Schnitzler’s syndrome (SchS) skin tissue. Neutrophils (Alexa 488-MPO–green) undergoing NETosis (subnucleosomal
complex Histone H2A, H2B, chromatin Alexa 594–red) are demonstrated by extracelluar co-localization of subnucleosomal complex and MPO. Nuclei are
counterstained with DAPI (blue) (original magnification 1,000x).
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FIGURE 3 | NETosis - immunoreactivity score in %: High NETosis rates in lesional dermis of Schnitzler’s syndrome (SchS) patients as well as Sweet syndrome (SwS)
patients and pyoderma gangrenosum (PG) patients. In lesional skin of Cryopyrin-associated periodic syndrome (CAPS) patients, only single neutrophils underwent
NETosis. In n = 2/5 patients with urticarial vasculitis patients (UV) NETting neutrophils (single cells or aggregated NETs) were detected. Absence of NETosis rates in
lesional dermis of CSU patients. Bars indicate median values. Exemplified fluorescence images showing dense neutrophilic infiltration with marked and aggregated
NET formation characterized by nuclear expansion and extracellular web-like DNA-fibers in the lesional dermis of a SchS patient (top), SwS patient (middle) and PG
patient (bottom). Neutrophils (Alexa 488-MPO - green) undergoing NETosis (subnucleosomal complex Histone H2A, H2B, chromatin Alexa 594 – red). Nuclei are
counterstained with DAPI (blue) (original magnification 400x).
RESULTS
The Lesional Skin of Patients With SchS Is
Characterized by Abundant Infiltrates of
Neutrophils That Undergo NETosis
Lesional skin of SchS patients showed stronger neutrophilic cell
infiltrates as compared to CSU (Figure S1). Immunofluorescence
co-staining revealed marked and aggregated NET formation
in lesional skin of all untreated SchS patients (n = 8) with
highest median NETosis scores (68.54%) (Figures 1, 3). This
could be confirmed by confocal microscopy (Figure 2) which
demonstrated extracellular co-localization of subnucleosomal
complex and MPO in SchS lesional skin. Interestingly, marked
and aggregated NET formation was also present in lesional
dermal skin of patients with SwS, (median score 40.99%) and
PG (median score 65.28%) (Figure 3). Only single neutrophils
undergoing NETosis were observed in CAPS patients (median
score 4.17%), whereas n= 2/5 UV patients presented with single
or marked aggregated NETs (median score 0%) (Figure 3). There
was an absence of NETs in the skin of CSU patients (n = 5)
(Figures 1, 3; SchS vs. CSU p = 0.011) and healthy controls (n
= 10) (data not shown).
PMA-Stimulated Peripheral Blood
Neutrophils of SchS Patients Show Higher
NETosis Rates Than Healthy Controls
Blood neutrophils from the majority of canakinumab-treated
patients (n = 6/9 for 80min and 100min, n = 9/9 for
130min) and all untreated SchS patients showed higher NETosis
rates of PMA-stimulated (20 nM) blood neutrophils. NETosis
rates of PMA-stimulated blood neutrophils from SchS patients
increased over time compared to healthy control neutrophils
with significant difference after 100min (p = 0.045) and
130min (p = 0.007) of PMA-stimulation (Figures 4A,B).
However, considerable variability was observed in both groups
and between experiments. Incubation of neutrophils with
RPMI medium alone resulted in near absent NETosis rates
in both SchS patients and healthy controls. Patients on IL-
1 blockade (canakinumab; n = 6) showed similar results
compared to untreated patients (n = 3) without significant
differences between both patient groups (Figure 4B, # marked as
untreated patients).
Stimulation with individual or combined proinflammatory
cytokines IL-1β, IL-6, IL-8, IL-17 in different concentrations
and together with PMA showed higher NETosis rates of blood
neutrophils in single SchS patients, but there was no overall
statistical significance between patients and healthy controls
(data not shown).
SchS Sera Induce High Rates of NETosis in
Healthy Donor Neutrophils
Stimulation of healthy control neutrophils with serum of
untreated symptomatic SchS patients showed near absence
of NETosis rates, which is comparable to stimulation with
healthy control sera as well as to stimulation with RPMI
medium. Co-stimulation of healthy control neutrophils with
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FIGURE 4 | (A) Higher NETosis rates of blood neutrophils in Schnitzler‘s syndrome (SchS) patient vs. healthy control after 130min of PMA stimulation: Fluorescence
images of peripheral blood neutrophils of a patient with SchS compared to healthy control: NET formation of isolated neutrophils (subnucleosomal complexe Histone
H2A, H2B, chromatin Alexa 594 – red). Nuclei are counterstained with DAPI (blue) (original magnification 100x) (B) Higher NETosis rates of neutrophils in SchS vs.
healthy controls: NETosis rates in % of blood neutrophils in IL-1-inhibitor treated and untreated SchS patients (# marked untreated patients) vs. healthy controls after
80, 100, and 130min following 20 nM PMA stimulation. *patients with persistent joint/bone inflammation despite IL-1 blockade. (C) Higher NETosis rates after SchS
serum stimulated control neutrophils compared to control serum stimulation: NETosis rates in % of control blood neutrophils after stimulation with 0.05 nM PMA and
10% serum of symptomatic SchS patients and healthy controls. Bars indicate median values.
serum of untreated symptomatic SchS patients and sub-threshold
PMA (0.05 nM) disclosed significantly higher NETosis rates as
compared to control sera and sub-threshold PMA (p = 0.001)
(Figure 4C).
High NETosis Rates Significantly Correlate
With Increased Inflammation Markers
Due to the continuous anti-IL-1 blockade in the majority of
patients, inflammation markers were barely elevated. Still, a
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FIGURE 5 | Correlation between serum markers, physician global assessment (PGA), disease duration and NETosis rates: (A) Correlation between high NETosis rates
and high C-reactive protein (CRP) levels for 80min PMA stimulation in Schnitzler’s syndrome patients (p = 0.000; r = 0.970). No significant correlation between
(Continued)
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FIGURE 5 | NETosis rates and serum levels of (B) serum amyloid A (SAA), (C) total blood neutrophil count, (D) S100A8/9, (E) interleukin-1-receptor antagonist
(IL-1RA), (F) PGA or (G) disease duration was observed in Schnitzler’s syndrome patients. The dotted lines indicate normal values (CRP, SAA, neutrophil count,
S100A8/9, IL-1RA) and minimal disease activity (PGA).
strong correlation between high NETosis rates and high CRP
levels (for 80min PMA stimulation p = 0.000; r = 0.970) was
identified (Figure 5A). In contrast, no significant correlation
between NETosis rates and markers of subclinical inflammation
(SAA, S100A8/9, IL-1RA), neutrophil count, disease duration
or clinical disease activity assessed by PGA was observed
(Figure 5). Also, we could not detect a significant correlation
between NETosis rates of symptomatic SchS patients and
immunoglobulin levels. The two SchS patients with the lowest
NETosis rates had persistent joint and bone pain despite IL-1
blockade (Figure 4B, ∗ marked patients with persistent joint and
bone pain). Vice versa, 2 out of 3 patients with high NETosis rates
had only mild bone pain/arthralgia.
DISCUSSION
Our results demonstrate increased amounts of neutrophils
undergoingNETosis in lesional skin and peripheral blood of SchS
patients as compared to CSU and/or healthy controls. To the best
of our knowledge, this is the first study which reports NETosis in
SchS. Furthermore, it supports the significance of NET formation
in autoinflammatory diseases as previously described for FMF
and gout (9, 14).
Neutrophils undergoing NETosis in lesional skin of SchS
patients and their absence in CSU patients may explain
the clinical observation of more solid and stable wheals
with longer duration in autoinflammatory patients compared
to urticarial lesions in CSU patients (15). In contrast to
SchS, lesional skin of CSU patients usually shows rather
sparse lymphocytic infiltrates and fewer neutrophils (4). The
spectrum of UV varies from only mild urticarial lesions
to severe disease with systemic manifestations which could
explain the heterogeneity of UV patients regarding the
occurrence of NETs in lesional skin. Clinical phenotypes of
neutrophilic dermatoses include pustular, urticarial, plaque-like,
and ulcerous lesions. All of them are commonly associated
with systemic diseases such as hematologic, autoimmune and
autoinflammatory entities (5). The presence of NETs in SwS and
PG suggests that NETosis contributes to the pathogenesis of
other neutrophilic dermatoses as well. This is underscored by a
very recent publication showing that enhanced NET formation
and decreased NET degradation contribute to the inflammation
in the hereditary autoinflammatory disease Pyogenic arthritis,
pyoderma gangrenosum and acne (PAPA) syndrome (16).
Although neutrophilic dermatoses are clinically heterogenous
disorders linked to either autoimmune or autoinflammatory
pathways, they share the activation of neutrophils that could
be elicited via alterations in homeostasis or chemotaxis of
neutrophils (17).
NETosis was previously associated with skin inflammation
in psoriasis and SLE (7, 8). Psoriasis is characterized by
epidermal hyperproliferation and neutrophil infiltrates invading
the epidermis. As expected, NETosis was primarily observed
in the epidermis next to keratinocytes (7), whereas in SchS
epidermal involvement is missing, and neutrophil infiltrates
undergoing NETosis are dermally located as can also been seen
in SLE (8).
A dual role for NETs was implicated in the pathophysiology of
inflammatory diseases. In prototype autoimmune disease
SLE, NETs induce the expression of double stranded
DNA (dsDNA) and LL-37, resulting in externalization of
autoantigens and immunostimulatory proteins (8). These
may contribute to an antigenic source for autoantibodies
that promote the inflammation and damage of endothelial
cells by synthesis of proinflammatory cytokines or type
I interferons in SLE (8). On the other hand, NETs may
limit the inflammation as suggested for autoinflammatory
disorders gout and FMF (9, 14). Aggregated NETs in gout
were shown to contribute to the resolution of inflammation
by degrading cytokines and chemokines via serine proteases
(14). In FMF, neutrophils were demonstrated to release IL-1ß
through NETs, but they also downregulated further NETosis
and thereby resolved FMF attacks via a negative feedback
mechanism (9).
NETosis rates in psoriasis patients correlated well with
clinical disease activity (7). Although this was not the case in
our study, we observed a positive correlation between high
NETosis rates and increased inflammatory marker CRP in
SchS. We hypothesize that the systemic inflammation drives
NET formation in SchS. These NETs may exert both pro-
and anti-inflammatory functions. NETosis could stimulate
aberrant NLRP3 inflammasome activation in SchS monocytes
and macrophages via cathelicidins and thereby enhance the
release of inflammatory cytokines followed by further NETosis
as shown for SLE (18). Also, NETs may support the resolution
of inflammation by degrading cytokines locally in SchS
(Figure 6). As in gout inflammation, high amounts of aggregated
neutrophils were found in lesional tissue of SchS patients.
The inflammation-limiting ability of NETosis via cytokine
degradation could explain the observation that SchS patients with
low NETosis rates suffer from persistent chronic joint and bone
inflammation as degradation of cytokines may not be sufficient
in these patients.
In lesional skin of patients with prototype autoinflammatory
urticarial syndrome CAPS, we observed only single neutrophils
undergoing NET formation. This finding may indicate
a pathophysiological link of NET formation and SchS-
specific paraproteinemia. Nevertheless, we could not
show a significant correlation between NETosis rates and
immunoglobulin levels, and there is no evidence for a
link between paraproteinemia and NET formation in other
diseases associated with paraproteinemia. However, aberrant
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FIGURE 6 | Main hypothesis on the pathophysiological role of neutrophil extracellular traps (NETs) in Schnitzler’s syndrome: Mast cells hypersensitive to
damage-associated molecular patterns (DAMPs) or pathogen-associated molecular patterns (PAMPs), are activated via Toll-like receptors (TLRs) and
(Continued)
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FIGURE 6 | produce Interleukin (IL)-1ß and IL-6. Cytokine production by mast cells is presumably mediated via the NLRP3 inflammasome. These proinflammatory
cytokines lead to neutrophil recruitment from peripheral blood. Cytokines and other serum factors induce initial NET formation in the skin. During NETosis, IL-17 and
LL-37 (cathelicidin) are secreted. IL-17 induces further neutrophil recruitment, while LL-37 activates the NLRP3 inflammasome in macrophages to produce further
IL-1ß, which again recruits neutrophils. Additional NETting neutrophils aggregate and secrete serine proteases such as proteinase 3 and elastase which degrade
cytokines (e.g., IL-1ß) and limit inflammation.
inflammasome component expression is described in both SchS
and multiple myeloma (19, 20).
The pathophysiologic mechanisms of how neutrophils are
activated to undergo NETosis locally in the lesional tissue as
well as systemically in the peripheral blood of SchS patients,
are unclear. Our results of higher NETosis of donor neutrophils
induced by SchS serum compared to healthy serum are in
line with the findings in psoriasis and support the existence
of a potential serum factor inducing NETosis (7). Several
proinflammatory cytokines, including IL-1ß, IL-6, and IL-17
were shown to be elevated in the serum of different inflammatory
conditions such as sepsis, diabetes and rheumatoid arthritis
and to induce enhanced NETosis of peripheral neutrophils in
these disorders (12, 21, 22). These cytokines are known to
be upregulated in SchS as well (3, 4). Interestingly, mast cells
induce neutrophil recruitment and were shown to be a source
of IL-1β and IL-6 in lesional skin of SchS patients (3, 4).
Whether these proinflammatory cytokines e.g., produced by
mast cells or even neutrophils themselves contribute to NET
formation locally in lesional skin of SchS patients remains
to be elucidated. However, none of these cytokines, whether
alone or in combination, could induce NETosis of peripheral
neutrophils in our study, and we are assuming that additional
factors are needed to stimulate neutrophils to form NETs
in SchS.
Limitations of our study comprise the relatively small
patient number, which is explained by the rarity of SchS
and the heterogeneity of individual experiments showing
considerable variability.
In conclusion, our results suggest that skin and systemic
inflammation in SchS are associated with neutrophils
undergoing NETosis. These may exert pro-inflammatory or
in the case of aggregated NETs anti-inflammatory properties.
For the future, evaluation of drivers of NET formation in
autoinflammatory diseases are essential in order to better
understand disease mechanisms. Also, these studies may help to
identify therapeutic targets that promote cytokine degradation
and resolution of inflammation via enhancing aggregation
of NETs.
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Table S1 | Main clinical, biological, and therapeutic features of Schnitzler’s
syndrome patients included in this study. ∗Patients were untreated when NETosis
rates were assessed. #NETosis rates were assessed in untreated and treated
patients.
Figure S1 | Hematoxylin-Eosin staining of infiltrates in lesional skin of patients with
Cryopyrin-associated periodic syndrome (CAPS), Schnitzler’s syndrome (SchS),
Sweet-Syndrome (SwS), Pyoderma gangrenosum (PG), chronic spontaneous
urticaria (CSU), urticarial vasculitis (UV), and healthy controls (original magnification
50x, 200x). Images are published in part in Bonnekoh (13).
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